Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of terfenadine and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.
Hôpital Lariboisière-Service de Rhumatolologie, Paris, France
Investigational Site Number, Canada, Canada
Stanford Health Care, Redwood City, California, United States
Clinical Trial Site, Auckland, New Zealand
London Health Sciences Centre, London, Ontario, Canada
Research Site, Sevilla, Spain
Centre de Recherche Clinique, HUG, Rue Gabrielle Perret-Gentil 4, Genève, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.